Novavax (NVAX) shares surged 19.5% due to increased trading volume and FDA progress

From Nasdaq: 2025-04-24 01:48:00

Novavax (NVAX) shares surged 19.5% to $7.47, driven by increased trading volume. The FDA requested more data on their COVID-19 vaccine, causing a delay in full approval but signaling progress. Earnings are expected to be $0.19 per share with a 118.1% YoY change and $71.84 million revenue, down 23.5%. NVAX currently holds a Zacks Rank #3 (Hold).

In the same industry, BioNTech (BNTX) stock rose 9.7% to $114.83. Their upcoming EPS estimate is -$2.77, -95.1% YoY change. The consensus estimate has risen by +8.5% in the past month. BNTX also has a Zacks Rank #3 (Hold). Global semiconductor manufacturing is projected to grow from $452 billion in 2021 to $803 billion by 2028.



Read more at Nasdaq: Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?